Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...
The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback